A Proof-of-concept Study to Assess the Effect of MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants.
Phase of Trial: Phase I
Latest Information Update: 30 May 2016
At a glance
- Drugs MMV 390048 (Primary)
- Indications Falciparum malaria
- Focus Proof of concept; Therapeutic Use
- 19 May 2016 Status changed from recruiting to completed.
- 17 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 05 Nov 2014 New trial record